ENHANCING QUALITY OF LIFE: INTEGRATIVE PALLIATIVE APPROACHES IN THORACIC SURGERY

Author
İSMAİL DAL

BİDGE

BIDGE Publications

ENHANCING QUALITY OF LIFE: INTEGRATIVE PALLIATIVE APPROACHES IN THORACIC SURGERY

Author: İSMAİL DAL

Editor: Dr. Öğretim Üyesi Güler Gülsen Ersoy

ISBN: 978-625-372-636-2

Page Layout: Gözde YÜCEL

1st Edition:

Publication Date: 26.03.2025

BIDGE Publications,

Certificate No: 71374

www.bidgeyayinlari.com.tr - bidgeyayinlari@gmail.com

Krc Bilişim Ticaret ve Organizasyon Ltd. Şti.

Güzeltepe Mahallesi Abidin Daver Sokak Sefer Apartmanı No: 7/9 Çankaya / Ankara

CONTENTS

Introduction

Palliative care, integral to holistic patient management, particularly in the realm of thoracic surgery, has undergone a significant transformation towards a more patient-centered approach. This shift acknowledges the complex interplay between the physical, psychological, and social aspects of patient care, aiming to enhance quality of life for both patients and their families. The prevalence of lung cancer and other debilitating thoracic conditions necessitates palliative interventions that are not only timely but also tailored to individual patient needs.

A patient-centered approach in palliative care emphasizes the patients' personal values and preferences, allowing for a care plan that aligns with their goals of care. Such approaches have shown to reduce patient anxiety, improve overall satisfaction with care, and even extend survival in some contexts [1-4]. In thoracic surgery, where patients often face severe symptom burdens postoperatively, integrating palliative care can mitigate symptoms and support decision making.

Moreover, communication plays a pivotal role in the implementation of patient-centered care. Effective communication between healthcare providers and patients, which includes detailed discussions about prognosis, potential interventions, and care preferences, is essential for aligning treatment with patient wishes. This is particularly critical in thoracic surgery, where surgical outcomes and recovery processes can vary widely [5].

The interdisciplinary nature of palliative care involves various specialists—surgeons, nurses, pain management experts, and social workers—to collaboratively formulate and execute a care plan tailored to the patient's needs. This team approach not only facilitates comprehensive symptom management but also addresses emotional and spiritual needs, which are often prominent in patients undergoing thoracic procedures [6].

Research has highlighted the importance of early integration of palliative care in the treatment trajectory of thoracic surgery patients, demonstrating improved outcomes and enhanced patient and family satisfaction [7]. Early palliative interventions can lead to better management of symptoms, less aggressive care at the end of life, and reduced healthcare costs [8].

In conclusion, patient-centered palliative care in thoracic surgery is not merely an adjunct to traditional medical treatment but a fundamental component of modern surgical practice. By focusing on the patient's quality of life, aligning medical interventions with patient values, and utilizing an interdisciplinary team, thoracic surgery can effectively address the multifaceted needs of patients at critical times.

Advanced Palliative Techniques in Thoracic Surgery

The domain of thoracic surgery encompasses a range of palliative techniques tailored to alleviate symptoms and improve the quality of life for patients suffering from advanced thoracic malignancies and other non-malignant thoracic conditions. These techniques are designed to manage complications and symptoms such as dyspnea, pain, and pleural effusion, which significantly impact patient well-being.

Indwelling Pleural Catheters

Indwelling pleural catheters (IPCs) have emerged as a pivotal tool in the management of recurrent pleural effusions, particularly in malignant pleural effusion (MPE). MPE is a common complication of advanced malignancies and carries a poor prognosis with median survival of only 3–12 months. The primary goal in treating MPE is palliative – to relieve symptoms (chiefly dyspnea and cough) and improve quality of life, as no intervention prolongs survival. Traditional approaches centered on pleural fluid drainage and pleurodesis via chest tubes or thoracoscopic talc insufflation [9]. However, since the late 1990s IPCs have revolutionized care by enabling outpatient fluid management. This chapter provides a comprehensive overview of IPCs, including their clinical indications, insertion technique, maintenance, outcomes, complications, historical development, and a comparison with other drainage methods. The discussion integrates evidence from landmark studies and global practice patterns, offering thoracic surgeons an evidence-based perspective on utilizing IPCs in modern pleural disease management.

Recurrent pleural effusions cause significant symptom burden. Most MPE patients experience disabling dyspnea and cough due to fluid re-accumulation. After a single therapeutic thoracentesis, a high percentage will have fluid reaccumulate, often within weeks. Thus, definitive interventions are usually required to provide sustained relief. The two broad strategies are pleurodesis or chronic drainage with an indwelling catheter. Patient selection is key: intervention is reserved for symptomatic effusions, and typically first preceded by a diagnostic/therapeutic thoracentesis to confirm symptom relief and lung re-expansion. If the lung fully expands and the patient is a candidate, pleurodesis or IPC are both options. However, in cases of non-expandable lung – where a malignant peel or visceral pleural restriction prevents lung re-

expansion – pleurodesis will fail, making an IPC the preferred definitive treatment. Trapped lung occurs in an estimated proportion of malignant effusions and is an important indication for IPC use.

Common indications for IPC placement include recurrent malignant pleural effusion causing dyspnea, especially if life expectancy is limited or if prior pleurodesis failed; non-expandable lung due to malignancy, where pleurodesis is contraindicated; refractory benign effusions in select cases; and chronic pleural infection in poor surgical candidates. While not the original target population, IPC use has expanded to certain benign pleural effusions. Caution is required, as infection risk is higher in patients with hepatic hydrothorax. In contrast, benign effusions like chylothorax or effusions in end-stage renal or cardiac disease have been managed with IPC when other options are exhausted. On occasion, tunneled pleural catheters have been used to manage chronic empyemas when open surgery is not feasible. This is off-label and data are limited, but small series suggest it can be a temporizing measure.

Originally, IPCs were developed for patients with MPE who were not ideal pleurodesis candidates. The first IPC was introduced in the 1990s. Early clinical studies demonstrated that IPCs could be placed safely and improve dyspnea in cancer patients. Over the ensuing decades, multiple trials have validated IPCs as an effective therapy for MPE. In randomized trials comparing IPC to chest tube talc pleurodesis in MPE, equivalent dyspnea improvement was found at 6 weeks, with some trials showing better sustained relief with IPCs at 6 months. Quality-of-life metrics were similar between groups. In subsets with trapped lung, IPCs unsurprisingly confer better outcomes, since pleurodesis cannot succeed if the lung is entrapped. With this evidence, clinical guidelines now endorse IPCs as a first-line option for malignant effusions, equal to pleurodesis, tailored to patient preference and clinical factors. The use of IPCs

has expanded globally: both thoracic surgeons and interventional pulmonologists routinely employ them.

IPCs are typically inserted as a minimally invasive procedure under local anesthesia. Adequate operator training and ultrasound guidance are crucial for safe placement. The patient is placed in a position that maximizes access to the effusion. Ultrasound is used to identify the fluid pocket and optimal insertion site. The insertion sites are infiltrated with local anesthetic. The chest wall is prepped and draped sterilely. Two small skin incisions are made: one at the planned pleural entry site and a second incision typically 5–10 cm away, anterior and inferior, where the catheter will exit the skin. A subcutaneous tunnel is then created between these two incisions. The catheter's polyester cuff will later reside in this tunnel to promote tissue ingrowth and secure the catheter, as well as reduce infection risk. Using Seldinger technique, a needle is inserted at the pleural entry site until pleural fluid is aspirated. A guidewire is passed through the needle into the pleural space, then the needle is removed. A dilator or peel-away sheath is advanced over the guidewire to enlarge the tract. The IPC is then fed through the sheath into the pleural space, ensuring all fenestrations are well inside the pleural cavity. The catheter is then pulled gently through the tunnel until the polyester cuff lies within the subcutaneous tunnel. The catheter is secured. The external portion of the catheter is left with its valve accessible. After insertion, a limited volume of pleural fluid is usually drained to relieve dyspnea while avoiding re-expansion pulmonary edema. A chest X-ray is obtained to confirm proper placement and rule out complications.

Patients and caregivers are instructed on draining the IPC, or home healthcare nurses visit to assist. Typically, drainage is performed two to three times per week or as needed to control symptoms. In many centers, a vacuum bottle system is used. Each bottle can remove up to one liter of fluid, and multiple bottles can be

used sequentially if needed. After drainage, the catheter valve is closed and capped. The exit site is dressed with a sterile dressing between uses. Patients are advised to maintain site cleanliness and report any signs of infection or catheter issues. The frequency of drainage can be tailored. Initially, regular drainage is common to prevent fluid reaccumulation and relieve symptoms. An alternative is daily drainage in an attempt to induce auto-pleurodesis. In practice, drainage frequency is often adjusted based on symptom relief and volume output. Over time, if drainage yields very low volumes on consecutive attempts and the patient's symptoms have resolved, this suggests that the pleural surfaces may have fused. In such cases, the IPC can be removed electively.

The tunnel tract usually seals around the catheter in the first week or two as the cuff epithelializes. Until then, a dressing is kept dry and changed every few days. Once the tract is mature, some centers allow dressings to be changed weekly. The external catheter is flushed only if obstructed. If blockage is suspected, one can attempt to instill a small volume of sterile saline and aspirate to clear debris. In some cases of loculated effusions causing poor drainage, intrapleural fibrinolytic therapy via the IPC has been reported, though this is not standard. Patients are generally seen in follow-up within one to two weeks after insertion to check the wound and ensure they are managing drainage. Thereafter, periodic check-ins monitor for complications and assess if the catheter can be removed. If and when it's time for IPC removal, the procedure is relatively straightforward. It is performed under local anesthesia. An incision is made to free the cuff from the subcutaneous tissue, and the catheter is pulled out. Studies indicate pleurodesis persists in the majority of patients after IPC removal for spontaneous pleurodesis. If an IPC is removed without pleurodesis, the effusion may recur and alternative management or another IPC can be considered.

IPCs primarily improve patients' symptoms and quality of life by controlling pleural fluid buildup. Symptomatic relief is often dramatic in the first days after insertion. Multiple studies have quantified these outcomes, finding significant dyspnea score improvements. Quality-of-life assessments likewise show no significant difference between IPC and pleurodesis patients over time. IPC therapy obviates the need for repeat invasive procedures in most cases. Once the catheter is in place, any re-accumulation of fluid can be managed by simple outpatient drainage. Patients avoid the cycle of repeated hospital visits for thoracentesis. A meta-analysis of available trials concluded that IPCs are at least as effective as talc pleurodesis in relieving dyspnea and improving quality of life, with the added benefit of reducing the risk of subsequent invasive pleural interventions.

A unique advantage of IPC therapy is that it obviates the need for repeat invasive procedures. Once the catheter is in place, any re-accumulation of fluid can be managed by simple outpatient drainage. Over time, a substantial proportion of patients will achieve spontaneous pleural symphysis. The continuous drainage promotes apposition of pleural surfaces and perhaps low-grade inflammation that can lead to the lung sticking to the chest wall. Reported spontaneous pleurodesis rates with IPC alone range from approximately 20% to 50%, depending on drainage strategy. More aggressive daily drainage can increase this rate. Instilling talc slurry through the IPC can further increase pleurodesis rates. Many patients are content to keep the catheter for life and simply drain periodically to stay symptom-free.

From a healthcare utilization perspective, IPCs shift management to the outpatient setting. Studies consistently show that IPC treatment results in a shorter initial hospital stay compared to pleurodesis which requires admission. Patients spending more time at home in their remaining lifespan prioritize avoiding hospital stays.

In terms of cost, IPC and pleurodesis are roughly comparable overall. Pleurodesis incurs higher up-front costs but little ongoing cost if successful. IPC has relatively low initial cost but incurs ongoing expenses. For patients with very short prognoses, IPC was more cost-efficient. Conversely, for those with longer survival, the cumulative supply costs of IPC could equalize or exceed pleurodesis costs. The decision should instead center on clinical and patient-centered factors.

No intervention for pleural effusion is without risks, but IPCs have proven generally safe and well-tolerated. Across many series and trials, serious complication rates are low, and most adverse events are minor and manageable. Infection is the most significant concern with any long-term indwelling device. IPC-related infections can manifest as cellulitis at the exit site or as pleural space infection. Reported infection rates are generally low. Most infections are superficial cellulitis around the tunnel or exit site; these can be treated with antibiotics without removing the catheter in many cases. Deeper infections are less common but more serious. The mortality attributable to IPC-related empyema is low. Comparisons of IPC versus pleurodesis find higher infection rates with IPC. Despite this, the absolute infection incidence with IPC remains low. Good sterile technique during drainage and proper tunnel placement of the cuff help minimize infections.

Tumor seeding along the catheter tract is a recognized complication, particularly with mesothelioma or metastatic adenocarcinoma. The incidence is relatively low. When it occurs, it is usually a later complication. Treatment of a tract metastasis, if symptomatic, may involve local radiotherapy or surgical excision. Over time, an indwelling catheter can become occluded by fibrin, debris, or loculated fluid collections. If an IPC stops draining due to obstruction, one can attempt flushing. If fluid becomes loculated in separate compartments, sometimes a second IPC might be placed or

intrapleural fibrinolytics can be administered. Occasionally, pleural fluid may leak to the skin if the tunnel tract is too short or if draining large volumes under high pressure. The polyester cuff and adequate tunnel length minimize this. Post-procedure pain at the insertion sites or along the tunnel is relatively common but usually mild and short-lived. Significant bleeding due to IPC insertion is very rare. Draining a very large effusion too rapidly can lead to re-expansion pulmonary edema. Adhering to drainage volume guidelines helps mitigate this.

Patients with IPCs are generally advised against submerging the catheter site in water. They should be given clear instructions on recognizing infection signs. During follow-up, any unexplained fever or new chest pain should prompt evaluation. If an infection occurs, early intervention with antibiotics is key. Multidisciplinary follow-up ensures the patient's overall disease is managed in concert with the IPC care. Encouraging communication can help address minor issues before they become major complications.

Indwelling pleural catheters have become an indispensable component of the management of recurrent pleural effusions. For thoracic surgeons, IPCs provide a less invasive alternative to traditional pleurodesis, enabling tailored, patient-centered care. IPCs achieve equivalent symptom relief to pleurodesis, with low complication rates and high patient satisfaction. They particularly shine in scenarios of trapped lung and in patients who prioritize outpatient therapy. The modern pleural disease specialist should be adept at both IPCs and pleurodesis, weighing the trade-offs of each approach to meet individual patient needs. Equipped with data from both historical studies and recent trials, the clinician can confidently discuss IPCs with patients as an equally efficacious alternative to pleurodesis. The choice should be individualized to relieve the patient's distress from breathlessness in the least burdensome way possible.

Bronchoscopic Interventions

Palliative bronchoscopic interventions play a crucial role in the management of patients with malignant central airway obstruction (CAO), particularly those with advanced lung cancer. These procedures aim to alleviate symptoms, improve quality of life, and, in certain cases, extend survival. This chapter provides an in-depth analysis of the current bronchoscopic techniques, comparing their efficacies, discussing alternatives, and highlighting recent advancements relevant to thoracic surgeons.

For central airway obstruction, which can severely impair respiratory function in patients with advanced lung cancer, bronchoscopic interventions such as stenting, laser ablation, and photodynamic therapy are utilized [10]. These procedures are minimally invasive, typically offering immediate relief of symptoms and improving airway patency [11].

Laser therapy utilizes the neodymium-doped yttrium aluminum garnet (Nd:YAG) laser, delivering high-intensity light to coagulate and vaporize obstructive lesions. The laser's penetration depth reaches up to 10 mm, allowing effective debulking of tumors. However, precise application is essential to prevent complications such as airway perforation or fire, necessitating maintenance of inspired oxygen concentrations below 40% during the procedure.

Electrocautery employs electrical current to generate heat, inducing tissue coagulation and vaporization. Compatible with both rigid and flexible bronchoscopes, electrocautery offers versatility with various electrode designs, including knives, snares, and blunt probes. Risks involve airway perforation and fire; thus, careful control of power settings and application duration is imperative.

Argon plasma coagulation (APC) uses ionized argon gas to deliver a non-contact thermal effect, causing superficial tissue coagulation with a penetration depth of 2–3 mm. Its non-contact

nature allows treatment of lesions in challenging anatomical locations. While effective for superficial lesions and hemostasis, APC is less suitable for debulking larger tumors due to limited penetration.

Photodynamic therapy (PDT) involves administration of a photosensitizing agent followed by exposure to specific light wavelengths, inducing selective tumor cell necrosis. The delayed therapeutic effect and requirement for multiple bronchoscopic sessions limit its use to patients with specific indications, such as superficial tumors or when other modalities are contraindicated.

Cryotherapy applies extreme cold to induce tissue necrosis, preserving extracellular matrix components and minimizing damage to surrounding structures. Cryotherapy is advantageous for obtaining biopsy samples and treating superficial lesions but is less effective for immediate debulking due to its delayed action.

Balloon bronchoplasty is a mechanical dilation method using inflatable balloons to widen stenotic airways, providing immediate relief of obstruction. However, the effects are often temporary, and restenosis is common, necessitating repeat procedures or adjunctive therapies.

Airway stenting maintains airway patency following debulking procedures. Stents can be silicone or metallic, each with specific advantages and complications, such as migration or granulation tissue formation.

In terms of efficacy, Nd:YAG laser and electrocautery provide immediate relief by effectively debulking tumors. APC offers effective hemostasis and is suitable for superficial lesions but is less effective for large tumor masses. PDT and cryotherapy have delayed effects, making them less suitable for patients requiring urgent symptom relief.

Regarding safety, cryotherapy and APC have favorable safety profiles due to their limited penetration depths, reducing the risk of perforation. In contrast, laser therapy and electrocautery carry higher risks of airway injury and fire, necessitating meticulous technique and precautions.

For durability, stenting provides longer-term airway patency but may be complicated by migration or granulation. Balloon bronchoplasty offers immediate results but often requires repetition due to restenosis.

Beyond bronchoscopic interventions, external beam radiotherapy (EBRT) serves as a non-invasive alternative or adjunct, particularly beneficial for patients unfit for bronchoscopy or with tumors inaccessible endoscopically. Combining EBRT with bronchoscopic debulking can enhance symptom relief and prolong airway patency.

Advancements in bronchoscopic technology have led to the development of navigational bronchoscopy and robotic-assisted procedures, enhancing the precision and safety of interventions. Personalized approaches, considering tumor characteristics, patient comorbidities, and available expertise, are essential in selecting the most appropriate intervention. Multidisciplinary collaboration remains pivotal in optimizing outcomes for patients with malignant CAO.

In conclusion, palliative bronchoscopic interventions offer vital options for symptom relief in patients with malignant airway obstruction. A thorough understanding of each technique's indications, benefits, and limitations is crucial for thoracic surgeons to tailor interventions effectively, ensuring optimal patient outcomes.

Pain Management

Pain management is another critical aspect of palliative care in thoracic surgery. Techniques such as intercostal nerve cryoablation during thoracotomy can significantly reduce postoperative pain and enhance recovery. Additionally, thoracic epidural analgesia has been shown to provide superior pain control and facilitate quicker mobilization compared to systemic opioid therapy [12].

Effective control of pain is not only critical for improving quality of life in patients with advanced thoracic malignancies but also essential for facilitating recovery following palliative surgical interventions such as pleurodesis, airway stenting, or tumor debulking. In these patients, pain may be multifactorial—originating from tumor invasion, nerve compression, pleural irritation, previous surgeries, or treatment-related complications. A nuanced understanding of the pathophysiology, coupled with an individualized approach to analgesia, is paramount.

Pain in thoracic malignancies may be nociceptive, neuropathic, or mixed. Nociceptive pain results from direct tumor involvement of chest wall structures, pleura, or bone, and is typically localized and responsive to opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). Neuropathic pain, on the other hand, arises from nerve infiltration or damage—such as brachial plexopathy in apical tumors or intercostal nerve irritation post-thoracotomy—and may be burning, tingling, or shooting in nature, requiring adjuvant medications. Mixed pain is common and often demands a multimodal strategy.

Opioids remain the gold standard for moderate to severe cancer-related pain. Morphine, oxycodone, hydromorphone, and fentanyl are commonly used. Route of administration should be adapted to the patient's condition and prognosis: oral for ambulatory

patients, transdermal for those with stable pain and poor oral intake, and intravenous or subcutaneous for rapid titration in acute settings. Long-acting formulations provide steady-state analgesia, while immediate-release opioids are critical for breakthrough pain. Fentanyl patches are especially useful in patients with dysphagia or gastrointestinal dysfunction. However, opioid-induced side effects—including constipation, nausea, sedation, and, less commonly, respiratory depression—must be proactively managed.

NSAIDs and acetaminophen provide valuable synergy when combined with opioids, particularly in bone or pleuritic pain. Although effective for somatic pain, NSAIDs carry risks of gastrointestinal bleeding, renal impairment, and cardiovascular events. Their use should be carefully evaluated in patients with co-morbidities or advanced disease.

Adjuvant analgesics are essential, particularly for neuropathic pain. Gabapentinoids (gabapentin and pregabalin) are first-line agents, modulating calcium channels and dampening neuronal hyperexcitability. Tricyclic antidepressants (amitriptyline, nortriptyline) and serotonin-norepinephrine reuptake inhibitors (duloxetine, venlafaxine) also show efficacy. Corticosteroids such as dexamethasone may reduce inflammation and edema around tumors or nerve roots, providing rapid symptom relief, particularly in cases of spinal cord compression or brachial plexus involvement.

Invasive interventions may be warranted in refractory pain. Intercostal nerve blocks, thoracic epidurals, and paravertebral blocks can provide targeted analgesia with fewer systemic side effects. Epidural analgesia, especially using a combination of local anesthetics and opioids, has shown significant benefit in postoperative and cancer-related chest wall pain. Thoracic paravertebral blocks offer comparable efficacy with a potentially lower risk of hypotension and urinary retention. In patients with

isolated rib metastases, radiotherapy can provide substantial pain relief and should be considered as part of a multidisciplinary plan.

For patients with more diffuse or intractable pain, neuraxial techniques such as intrathecal opioid delivery or neurolytic celiac plexus block (in upper abdominal involvement) may be employed. However, these techniques are invasive and best reserved for patients with longer prognoses and good functional status.

Non-pharmacological strategies are increasingly recognized as essential components of palliative pain management. Physical therapy can improve mobility and reduce stiffness associated with thoracic wall involvement. Cognitive-behavioral therapy (CBT), mindfulness, and relaxation techniques can modulate the perception of pain and help patients cope with existential distress. Integrative approaches, including acupuncture and massage therapy, although less evidence-based, are reported to offer symptom relief in many palliative care settings.

A key principle in palliative pain management is continuous reassessment. Pain should be evaluated using validated tools such as the Numeric Rating Scale (NRS) or Brief Pain Inventory (BPI), considering both intensity and impact on function. Dynamic pain—aggravated by movement, coughing, or breathing—is especially relevant in thoracic surgery and requires careful planning of analgesia timing and dosage.

Importantly, all pain management strategies must align with the patient's overall goals of care. In end-of-life situations, the emphasis may shift from minimizing side effects to maximizing comfort, even if sedation is an accepted consequence. Ethical considerations around opioid use, particularly fears of hastening death, must be openly addressed. Palliative sedation for intractable pain, while rare, may be appropriate in terminal phases under strict ethical guidelines and with interdisciplinary support.

Recent advancements in pain management include the use of liposomal bupivacaine for longer-lasting nerve blocks, patient-controlled analgesia systems tailored to palliative needs, and targeted molecular agents addressing cancer-induced neuropathy. Moreover, predictive tools are being developed to identify patients at higher risk of chronic post-thoracotomy pain, allowing earlier intervention.

In summary, pain management in palliative thoracic surgery demands a multimodal, interdisciplinary, and compassionate approach. From pharmacologic regimens tailored to the type and intensity of pain, to regional anesthesia techniques and supportive psychosocial strategies, the goal is not merely the reduction of pain scores, but the enhancement of life quality, dignity, and autonomy in patients facing advanced disease. Effective pain control, when integrated into a broader palliative care framework, empowers both patients and clinicians to navigate the complex terrain of serious illness with greater clarity and comfort.

Nutritional Support

Nutritional support plays a pivotal role in palliative care for thoracic surgery patients, as malnutrition can severely affect outcomes and quality of life. Nutritional interventions aim to maintain energy balance and improve protein intake, thereby supporting overall health and recovery. The integration of dieticians into the palliative care team ensures that nutritional strategies are personalized and effective.

In the context of palliative thoracic surgery, nutritional support represents a cornerstone of comprehensive patient care. Malnutrition is a common and often underrecognized issue in patients with advanced thoracic malignancies, particularly lung cancer and esophageal cancer. It results from a combination of factors including tumor-induced metabolic changes, treatment-

related side effects, and mechanical obstruction or dysfunction of the upper gastrointestinal tract or airways. Proper nutritional intervention not only improves quality of life but may also enhance response to treatment, reduce complications, and even prolong survival in selected patients.

Patients requiring palliative thoracic surgery frequently present with significant weight loss, sarcopenia, and cachexia. These conditions are driven by both reduced caloric intake and increased energy expenditure associated with systemic inflammation and tumor burden. Anorexia, early satiety, dysphagia, and odynophagia are common complaints that further compound nutritional deficits. In the presence of airway compression or tracheoesophageal fistulas, the risk of aspiration complicates oral intake and necessitates specialized feeding strategies.

Nutritional assessment must be an integral part of the preoperative and ongoing palliative care plan. Tools such as the Patient-Generated Subjective Global Assessment (PG-SGA), Nutritional Risk Screening (NRS-2002), and the Malnutrition Universal Screening Tool (MUST) offer practical and validated means to identify patients at risk. In thoracic surgical patients, unintentional weight loss exceeding 10% over six months, body mass index under 18.5, and serum albumin levels below 3.0 g/dL are indicative of clinically significant malnutrition and warrant aggressive nutritional intervention.

The approach to nutritional support should be individualized based on the patient's functional status, prognosis, level of obstruction, and overall goals of care. For patients able to tolerate oral intake, dietary counseling by a nutritionist or dietitian should focus on energy-dense, high-protein diets tailored to patient preferences and tolerance. In cases of poor appetite or dysphagia, oral nutritional supplements, appetite stimulants such as megestrol

acetate, and antiemetic or prokinetic agents can provide symptomatic relief and facilitate intake.

When oral intake becomes inadequate or unsafe due to disease progression, enteral nutrition is often the preferred route. Nasogastric feeding tubes may be used for short-term support, but they are often poorly tolerated and cosmetically undesirable in palliative care settings. For longer-term feeding, percutaneous endoscopic gastrostomy (PEG) or jejunostomy (PEJ) tubes are viable options. The decision between PEG and PEJ is determined by the location of the tumor, the presence of gastroesophageal reflux, and the risk of aspiration. In patients with proximal esophageal obstruction or high aspiration risk, jejunal feeding is generally preferred. However, the invasive nature of these procedures must be balanced against expected survival, symptom burden, and patient wishes.

Parenteral nutrition may be indicated in rare cases when enteral feeding is contraindicated or not feasible. Examples include malignant bowel obstruction, severe gastrointestinal toxicity from chemoradiotherapy, or complications like tracheoesophageal fistulas with uncontrolled aspiration. While total parenteral nutrition (TPN) can stabilize nutritional status and support patients through surgery or radiotherapy, it carries significant risks including catheter-related infections, liver dysfunction, and electrolyte imbalances. In the palliative setting, its use should be limited to carefully selected patients with a clear benefit and a realistic life expectancy that justifies the intervention.

An essential consideration in nutritional support is the ethical dimension of feeding at the end of life. Artificial nutrition may not provide comfort or prolong life in the terminal phase and may instead contribute to distress through complications and interventions that are no longer aligned with the patient's goals. Multidisciplinary

discussions with patients and families, focusing on expectations, potential benefits, and burdens of nutritional support, are critical in ensuring that care remains patient-centered and humane.

Emerging approaches in nutritional care for palliative thoracic surgery patients include immunonutrition and anabolic interventions. Diets enriched with omega-3 fatty acids, arginine, and nucleotides have shown promise in modulating inflammation and improving outcomes in surgical patients, although evidence in the palliative setting remains limited. The use of anabolic agents such as testosterone derivatives and exercise programs tailored to the patient's abilities may help preserve lean body mass and function, particularly in those undergoing neoadjuvant therapy or repeated procedures.

Incorporating nutritional support into the broader palliative care framework ensures that patients undergoing thoracic surgery for symptom relief—such as debulking procedures, airway stenting, or pleurodesis—have optimized physiological reserves to tolerate interventions and recover meaningfully. Nutrition also interacts closely with other symptom management domains, including pain control, respiratory support, and psychological care, reinforcing its foundational role in holistic patient management.

In conclusion, nutritional support in palliative thoracic surgery is not merely an adjunct to treatment but a central therapeutic pillar. It requires careful assessment, a tailored and dynamic approach, and a sensitivity to patient goals and preferences. As the field continues to evolve, thoracic surgeons must collaborate closely with dietitians, palliative care teams, and oncologists to deliver compassionate, evidence-based care that honors both the science and the humanity of medicine.

Superior Vena Cava Syndrome

In cases of superior vena cava syndrome, which is predominantly caused by malignancies such as lung cancer and mediastinal tumors, palliative surgical options may include stenting and occasionally bypass surgery to relieve symptoms and improve venous circulation [13]. These interventions are critical as they address both the physical discomfort and the psychological distress associated with this condition.

Superior vena cava syndrome (SVCS) represents a critical clinical entity in thoracic medicine, characterized by the obstruction of venous return through the superior vena cava (SVC), often due to extrinsic compression, intravascular thrombosis, or direct invasion by adjacent pathologies. Historically linked to advanced malignancies—particularly lung cancer, lymphomas, and metastatic disease—SVCS has seen a shifting etiological landscape, with benign causes such as intravascular device-related thrombosis or fibrosing mediastinitis rising in prevalence due to increased use of central venous catheters and cardiac devices. This syndrome demands prompt recognition and tailored management to alleviate potentially life-threatening symptoms and address underlying causes, making it a pivotal concern for thoracic surgeons, oncologists, and interventional radiologists alike.

The pathophysiology of SVCS revolves around impaired blood flow from the upper body to the right atrium, leading to venous hypertension. This manifests as facial and upper extremity edema, dyspnea, cough, and dilated collateral veins across the chest and neck. In severe cases, cerebral edema or laryngeal swelling may ensue, posing risks of altered mental status or airway compromise. The clinical presentation varies based on the acuity and completeness of obstruction, with chronic cases often developing collateral circulation that mitigates symptoms. Malignant etiologies,

accounting for 60–85% of cases, typically present abruptly due to rapid tumor growth, while benign causes may follow a more insidious course.

Diagnosis begins with a high index of suspicion in patients with suggestive symptoms and risk factors. Imaging serves as the cornerstone: contrast-enhanced computed tomography (CT) delineates the site and extent of obstruction, while magnetic resonance venography (MRV) or Doppler ultrasound may assess collateral flow and thrombotic burden. In malignancy-associated SVCS, tissue biopsy—obtained via bronchoscopy, mediastinoscopy, or endobronchial ultrasound (EBUS)—is critical to confirm histology and guide therapy. Differentiating malignant from benign causes is essential, as management strategies diverge significantly. For instance, intravascular thrombosis secondary to central venous catheters necessitates anticoagulation, whereas malignant compression may require stenting or oncologic therapies.

Emergent management focuses on symptom relief and preventing complications. Elevating the head of the bed and administering supplemental oxygen can reduce venous pressure and improve dyspnea. Glucocorticoids (e.g., dexamethasone) are empirically used to decrease tumor or inflammatory edema, though their benefit in non-lymphomatous malignancies remains debated. Diuretics provide transient relief but risk dehydrating patients. In thrombotic cases, anticoagulation with low-molecular-weight heparin or direct oral anticoagulants is initiated, while catheter-directed thrombolysis may be considered for acute, extensive thrombosis. Endovascular stenting has emerged as a first-line intervention for malignant SVCS, offering rapid symptom resolution in over 90% of cases, often within 48 hours. Self-expanding metal stents are preferred due to their flexibility and radial force, though complications like migration, thrombosis, or perforation necessitate close monitoring.

Definitive treatment targets the underlying cause. For malignancies, chemotherapy and radiation therapy remain mainstays, particularly for small cell lung cancer or lymphomas highly responsive to these modalities. In non-small cell lung cancer, immunotherapy and targeted therapies have shown promise in reducing tumor burden. Surgical bypass (e.g., spiral vein or prosthetic grafts) is reserved for refractory benign cases or when stenting fails. Benign etiologies, such as mediastinal fibrosis or granulomatous diseases, may require long-term immunosuppression or antifungal therapy.

Collaborative care is paramount. Multidisciplinary teams—including thoracic surgeons, interventional radiologists, oncologists, and palliative care specialists—ensure holistic management. For instance, while stenting provides immediate relief, coordinating with oncologists ensures systemic disease control, and palliative care addresses quality of life in advanced cancer. Ethical considerations arise in terminal patients, where balancing aggressive interventions with comfort-focused care becomes essential. Shared decision-making, guided by patient preferences and prognosis, is critical—particularly when life expectancy is limited.

Complications of SVCS management include stent-related issues (e.g., restenosis, infection), bleeding from anticoagulation, or radiation-induced esophagitis. Long-term surveillance with imaging and clinical evaluation detects recurrence or progression. In pediatric populations, SVCS is rare but may stem from congenital heart defects, post-surgical scarring, or malignancies like neuroblastoma, necessitating age-specific approaches to minimize procedural risks and address growth-related anatomical changes.

Future directions in SVCS management emphasize minimally invasive techniques and personalized medicine. Advances in bioresorbable stents, drug-eluting devices, and

improved anticoagulation protocols aim to reduce complications. Molecular profiling of tumors guides targeted therapies, potentially decreasing reliance on mechanical interventions. Additionally, machine learning models to predict obstruction risk or stent patency are under exploration.

In conclusion, SVCS management requires a nuanced, multidisciplinary approach that integrates rapid symptom control with definitive treatment of the underlying pathology. Thoracic surgeons play a central role in diagnosing, intervening, and coordinating care, particularly in complex or refractory cases. By leveraging advances in endovascular techniques and systemic therapies, clinicians can significantly improve outcomes and quality of life for patients with this challenging syndrome.

End of Life Care

End-of-life care is an integral part of palliative thoracic surgery, where the focus shifts entirely to comfort and quality of life. Discussions around advance care planning and end-of-life care options are essential to align the medical interventions with the patient's and family's wishes, ensuring dignity and respect in the final stages of life.

Central to end-of-life care are ethical principles that guide decision-making. Respecting patient autonomy is paramount, achieved through advance care planning and shared decision-making that honors individual preferences. Surgeons must also uphold beneficence by prioritizing symptom relief while avoiding futile treatments that may prolong suffering. Equitable access to palliative resources, regardless of cultural or socioeconomic background, underscores the principle of justice. Effective communication is critical in this context. Frameworks like SPIKES (Setting, Perception, Invitation, Knowledge, Empathy, Summary) or BREAKS (Background, Rapport, Explore, Announce, Kindling,

Summarize) help structure difficult conversations about prognosis and goals of care. Cultural sensitivity is equally vital, as attitudes toward death, truth-telling, and family involvement vary widely—particularly in collectivist cultures where family members may assume decision-making roles. Proactively mediating conflicts between families and care teams ensures alignment with patient-centered goals.

Recognizing the transition to end-of-life care requires vigilance. Prognostic indicators such as declining performance status (e.g., ECOG scores), cachexia, recurrent hospitalizations, or resistance to disease-modifying therapies signal this shift. Disease-specific trajectories further inform clinical judgment. For example, lung cancer patients often experience rapid decline after immunotherapy or chemotherapy failure, while mesothelioma patients suffer progressive dyspnea and pleural effusions. Symptom management becomes the priority at this stage. Dyspnea, a common and distressing symptom, is managed with opioids like morphine, supplemental oxygen, or non-invasive ventilation. Pain control relies on multimodal analgesia, combining NSAIDs, opioids, and adjuvants, alongside interventional techniques such as nerve blocks. Cough and hemoptysis may require antitussives (e.g., codeine), bronchoscopic interventions, or palliative radiotherapy. Psychological distress, including anxiety and depression, necessitates collaboration with psychiatry to ensure holistic care.

Decision-making challenges abound during this transition. Surgeons may grapple with emotional attachment to curative goals or fear of "giving up," while patients and families might misinterpret palliative care as abandonment. Prognostic tools like the Palliative Prognostic (PaP) Score can objectively guide these conversations. When faced with requests for futile treatments, a structured approach—empathizing with concerns, educating on realistic outcomes, exploring alternatives, and aligning care with overarching

goals—helps navigate these emotionally charged discussions. Legal and ethical considerations further complicate decision-making. Advance directives, living wills, and POLST forms clarify patient wishes, while distinctions between withholding care (e.g., not initiating mechanical ventilation) and withdrawing care (e.g., discontinuing life support) require both moral and legal clarity. Palliative sedation, aimed at relieving refractory symptoms, must be ethically differentiated from euthanasia, with adherence to jurisdictional laws.

Collaborative care models are indispensable in end-of-life management. Multidisciplinary teams—including palliative care specialists, nurses, social workers, and chaplains—should be integrated early to address physical, emotional, and spiritual needs. Thoracic surgeons play a pivotal role in leading family meetings, clarifying the limits of surgical intervention, and advocating for timely hospice referrals. Supporting families and caregivers is equally crucial. Preparing them for imminent death involves discussing expected signs, such as Cheyne-Stokes breathing or decreased responsiveness, to reduce distress. Post-death, providing bereavement resources, including grief counseling and survivor networks, fosters long-term emotional healing.

Surgeon well-being cannot be overlooked. Moral distress, arising from ethically complex cases or perceived failures, requires debriefing sessions and peer support to mitigate burnout. Institutions must prioritize wellness programs and normalize training in end-of-life care to equip surgeons with resilience and compassion. Unique scenarios, such as managing catastrophic emergencies (e.g., massive hemoptysis) or postoperative complications in frail patients, demand pre-emptive palliative strategies. Pediatric thoracic surgery introduces additional ethical challenges, particularly in congenital or oncologic cases, where parental expectations and a child's prognosis must be carefully balanced.

In conclusion, end-of-life care in thoracic surgery transcends technical skill, embodying the art of medicine. By embracing their role as healers beyond the operating room, surgeons can alleviate suffering, honor patient autonomy, and provide profound comfort to patients and families. This chapter underscores the importance of integrating palliative principles early, fostering collaboration, and nurturing both patient and surgeon well-being.

In summary, palliative thoracic surgery utilizes a range of techniques aimed at symptom relief and enhancing quality of life. From managing pleural effusions and airway obstructions to pain control and nutritional support, each technique is tailored to meet the specific needs of the patient, underscoring the importance of a multidisciplinary approach in the delivery of effective palliative care.

Social Support Mechanisms, the Role of the Family, and the Impact of Religious Beliefs

Thoracic surgery patients face not only complex medical challenges but also profound psychosocial ones. A growing body of evidence indicates that the support systems surrounding a patient – family, institutional, community, and peer networks – along with the patient's religious or spiritual beliefs, can significantly influence the surgical journey and outcomes. These influences span the entire continuum of care, from preoperative preparation and postoperative recovery to long-term rehabilitation and end-of-life care. A holistic approach that addresses social support and spiritual needs, alongside clinical care, has been associated with better patient satisfaction, improved quality of life, and even measurable clinical benefits in thoracic surgery patients [14].

This chapter provides a comprehensive overview of how various social support mechanisms and religious beliefs impact thoracic surgery patients, critically evaluating the evidence from

Turkey and around the world, with particular emphasis on the palliative care setting.

Social support can come from multiple sources, but the family is often the cornerstone. Family members typically provide practical caregiving, emotional encouragement, and advocacy for patients undergoing thoracic surgery. Numerous studies have demonstrated the beneficial effects of strong family support on patient outcomes. For instance, a prospective study in Spain found that patients who reported higher family cohesion before surgery had significantly better postoperative recovery, as evidenced by faster convalescence and lower stress-hormone (cortisol) levels [15].

Patients with tightly knit families recovered more quickly and had less postoperative stress, whereas those with weaker family support and higher anxiety showed slower recovery [15].

These results align with broader research highlighting the positive impact of perceived family support on both mental and physical health [15].

In practical terms, family presence and involvement appear to mitigate preoperative anxiety and postoperative pain. A study of veterans undergoing major thoracic and abdominal operations observed that patients with larger social networks (more frequent contact with family and friends) reported less pain and required fewer opioids in the first five days after surgery [16].

Although that effect was partly mediated by lower baseline anxiety in well-supported patients, it was notable that having a smaller social network independently predicted a longer postoperative hospital stay [16].

This suggests that family and close friends can facilitate recovery by reducing patient stress and helping with care needs, thereby potentially shortening hospitalization.

Beyond emotional comfort, families can directly participate in care interventions that improve outcomes. In one randomized trial, training family members in simple postoperative care and delirium prevention techniques led to a drastic reduction in postoperative delirium among elderly surgical patients (2.6% incidence with family intervention vs 19.4% in controls) [17].

Delirium is a serious complication associated with longer stays and higher morbidity, so this finding underscores that engaging relatives as active caregivers can be a powerful resource. Especially for thoracic surgery patients – who are often older and at risk for complications like delirium – involving family in fundamental care (mobilizing the patient, assisting with meals and hydration, orienting and reassuring the patient) can improve safety and recovery. Such approaches leverage the natural presence of family at the bedside, effectively turning loved ones into extensions of the care team [17]

Culturally, this approach may be particularly relevant in countries like Turkey and China, where families traditionally take an active role in caring for hospitalized relatives [17, 18].

Indeed, during the COVID-19 pandemic in Turkey, a study noted that relatives of terminally ill patients maintained high levels of positive religious coping and a strong sense of responsibility for caregiving [19], reflecting the deep familial commitment to care.

Marital status has frequently been used as a surrogate marker for social support in research, and its effects on outcomes further highlight the importance of family. Large-scale analyses involving hundreds of thousands of cancer patients (including many with thoracic malignancies) have shown that being married is associated with significantly better treatment uptake and survival [14]

For example, Aizer et al. analyzed over 734,000 cancer cases and found that spousal support had a notable impact on both the

likelihood of receiving appropriate cancer therapy and on long-term survival [20].

Unmarried patients, lacking that immediate support, not only reported poorer quality of life but also had worse survival in several studies [14].

In lung cancer, which is often managed surgically by thoracic surgeons, married patients tend to present earlier, adhere better to treatments, and live longer than those who are single, divorced, or widowed [21].

One analysis of advanced-stage lung cancer patients from the U.S. SEER database found that the survival advantage of married patients was most pronounced in stage III–IV disease [22] precisely when strong support at home might help patients tolerate aggressive treatments or manage symptoms. These correlations are so consistent that some authors have suggested formally integrating social support interventions (for example, connecting unmarried patients with support services or patient navigators) as part of standard cancer care to improve outcomes [23].

The beneficial impact of family appears to operate through multiple pathways: practical help with appointments and medications, encouragement to pursue and complete therapies, and buffering of stress and depression. In Germany, a study of lung cancer patients and their spouses illustrated the nuances of familial support – women with lung cancer received less spousal support on average than men did, hinting at possible disparities in caregiver dynamics, yet emotional support from a partner was identified as the most crucial element regardless of gender [24].

Overall, the evidence strongly supports that engaged family support confers a protective effect on thoracic patients' wellbeing, whereas social isolation or lack of family has the opposite effect.

While family is pivotal, it is only one aspect of a patient's social support system. Institutional and community support mechanisms also play a significant role in thoracic surgical care, complementing what families provide. Hospitals and healthcare teams can create structured support through patient education, counseling, and coordinated care programs. For instance, specialized interdisciplinary programs have been developed to support thoracic surgery patients from hospital to home. One example is an Integrated Comprehensive Care (ICC) model in Canada that assigns a multidisciplinary team to coordinate discharge planning, home nursing, and follow-up for lung surgery patients [25].

In a propensity-matched study, patients enrolled in such an ICC program had a shorter median postoperative hospital stay (4 days vs 5 days) and markedly fewer emergency department visits (about 10% vs 28%) and readmissions (7% vs 9%) in the first 60 days after lung resection, compared to those receiving standard discharge care [25].

. The 60-day mortality was also slightly lower with the integrated support (0.6% vs 0.8%) [25].

. These improvements are attributed to better continuity of care – the program ensured that after leaving the hospital, patients had appropriate home care services and early intervention for problems [25].

What this means for thoracic surgeons is that robust institutional support systems can significantly reduce complications and healthcare utilization. By proactively managing pain, monitoring recovery, and supporting the family caregivers at home, such programs address needs that would otherwise overwhelm patients and relatives alone. Similarly, the involvement of hospital-based support staff – such as oncology social workers, case managers, physiotherapists, dietitians, and palliative care specialists

– provides essential resources. These professionals can educate patients and families on what to expect, help coordinate complex care across multiple providers, and offer counseling for emotional or practical challenges. A qualitative evaluation of thoracic surgery patients and caregivers in an integrated care program noted better experiences when there was clear communication, role clarification, and support for the caregiver–patient dyad, reducing caregiver burden and confusion [26].

In essence, institutional support fills gaps that a lay family may not be equipped to handle alone, such as managing advanced symptoms or navigating the healthcare bureaucracy.

Community support and peer support further expand the safety net around thoracic surgery patients. Community support can include local organizations, patient advocacy groups, religious congregations, or even informal networks of friends and neighbors who rally around the patient. In Turkey, where extended family and community ties are traditionally strong, patients often receive visits, prayers, and material support (like meals or transportation) from a wide circle of relatives and community members. This communal approach can bolster the patient's morale and reduce feelings of loneliness. However, modernization and urbanization have somewhat eroded the extended family structure in Turkey; as one report observes, the transition to more nuclear families has made it harder for families to single-handedly meet all care needs, increasing the importance of community and institutional supports [27].

Nonetheless, community health services – for example, home-based care nursing programs and non-governmental organizations – are starting to fill this void. Turkey's healthcare system in the past decade has established numerous palliative care centers and home-care regulations to support patients with serious illnesses [27], reflecting a policy recognition that community and

home support are critical as family capacity changes. Globally, volunteer organizations and charity groups (like the American Cancer Society or local cancer support charities) often provide services such as patient transport, home visits, or support hotlines, which can be lifelines for patients lacking other support.

Peer support, meaning support from other patients who have similar conditions or experiences, is another valuable element, particularly for coping and psychosocial wellbeing. Patients who undergo major thoracic surgeries (for example, lung cancer resections or esophagectomies) may benefit from speaking with others who have been through the same operation or diagnosis. Sharing experiences can normalize the fears and side-effects and provide hope by hearing survivor stories. Support groups specific to lung cancer or thoracic surgery patients exist in many countries; they can be face-to-face groups, or increasingly, online forums and social media communities connecting patients worldwide. Research indicates that patients often crave this type of understanding that family members, however well-intentioned, might not fully provide. In one study (John et al.), lung cancer patients reported that having family and friends nearby was extremely important for their quality of life, but they also noted a lack of disease-specific support groups and even a sense of stigma in general cancer support groups when surrounded by patients with other types of cancer [28].

Lung cancer in particular carries a stigma (often related to smoking history), which can make patients hesitant to join general cancer groups [28].

This finding suggests that peer support works best when it is tailored – thoracic patients feel more comfortable and validated among peers who share similar medical experiences or prognoses. Thoracic surgeons and oncologists can facilitate peer support by referring patients to such groups or connecting current patients with

willing former patients (a “buddy” system). While formal evidence on peer support improving clinical outcomes is limited and sometimes mixed, the qualitative benefit to patient outlook and knowledge is widely acknowledged. Even if peer support mainly boosts emotional well-being, that in itself can translate to better treatment adherence and coping. High perceived social support, regardless of source, has repeatedly been associated with improved quality of life in cancer patients.

A cross-sectional study from Turkey focusing on lung cancer patients found that those with higher overall social support (as measured by a Multidimensional Scale of Perceived Social Support) had significantly higher quality-of-life scores; notably, family support was most strongly correlated with better physical and emotional well-being [29].

This reinforces that all support sources – family, peers, or community – collectively contribute to how well a patient lives through and beyond treatment.

Religious and spiritual beliefs are another cornerstone in the psychosocial landscape of thoracic surgery patients, deeply influencing coping mechanisms and decisions throughout the surgical journey and especially in palliative care. Many patients draw upon faith or spiritual practices for comfort when facing life-threatening illnesses like lung cancer or advanced thoracic diseases. Globally, surveys show a majority of cancer patients consider spirituality or religion an important source of strength when dealing with illness.

Religion can imbue a sense of hope, meaning, and acceptance; for example, believing that one’s fate is in God’s hands or that suffering has purpose may help patients endure arduous treatments. In Turkey, where Islam is the predominant faith, religious coping is common among patients and their families. A

recent Turkish study during the COVID-19 era found that relatives of terminally ill patients had high levels of positive religious coping (e.g., seeking solace in prayer, trusting in God's plan) [19].

This indicates that families often use faith to bolster resilience in the face of a loved one's terminal illness. Positive religious coping strategies – such as prayer, reading scripture, or meeting with religious leaders – have been associated with lower distress and higher psychological well-being in serious illness, as long as the individual experiences their faith as supportive and benevolent. On the other hand, there is also something termed negative religious coping (e.g., feeling punished by God or abandoned spiritually), which can worsen anxiety or depression [19].

Fortunately, most studies suggest positive coping is far more common than negative among those who are religious.

For thoracic surgeons, understanding a patient's religious background can be crucial in delivering compassionate care. Religious beliefs might influence how a patient views the proposed surgery – some may see surgery and medicine as instruments of God's will, reinforcing their commitment to treatment, while others might prioritize miraculous healing or alternative remedies congruent with their beliefs. Importantly, religion can also affect end-of-life choices and palliative care utilization. In both Western and Turkish contexts, highly religious patients are sometimes more inclined to pursue aggressive life-prolonging treatments as death approaches. A notable study of terminal cancer patients in the United States found that those who rated religion as very important in coping were more likely to receive intensive interventions in their final days (such as ventilator support or ICU care), even though such care often correlated with worse quality of life at life's end.

The researchers observed that clinicians tended to honor these patients' wishes for maximal treatment, possibly because the

patients believed in the possibility of divine healing or felt that "giving up" was not in line with their faith.

Similarly, an analysis of Muslim patients (including many of Turkish origin) revealed that devout families sometimes urge continuation of treatment despite medical futility, driven by a belief that one must not limit God's omnipotence by forgoing available care [19].

Interviews with Turkish imams in Europe highlighted this dynamic: imams often counsel families to "show faith in God by seeking maximum treatment" and to avoid consenting to withdrawal of life support, out of fear that they would be accountable to God for not doing everything possible [19].

Families may hide their grief and maintain an upbeat demeanor around the patient to keep hope alive, as encouraged by religious guidance.

While these beliefs come from a place of hope and duty, they can conflict with medical realities in palliative care. Doctors might feel pressure to continue aggressive therapies that contradict clinical judgment of comfort-focused care.

This scenario is not unique to Turkey; similar patterns are seen among various faiths – for example, some Christian groups in the U.S. also opt for more aggressive end-of-life care and delay hospice enrollment when their religious community strongly emphasizes miraculous healing or "not giving up".

In fact, a study found that terminally ill patients well-supported by religious communities were less likely to enter hospice and more likely to die in ICUs compared to those who were less religious, unless their medical team actively engaged in end-of-life spiritual discussions.

These findings are a double-edged sword: on one hand, spirituality provides comfort and can improve patients' mental health; on the other, if not integrated into care planning, it may lead to choices that increase suffering or delay acceptance of palliative measures.

To harness the positive aspects of religious belief while mitigating potential negatives, healthcare providers should incorporate spiritual care into their practice. In palliative care settings, involving chaplains or spiritual counselors is considered a best practice internationally. In Turkey, there have been calls for more "holistic" approaches that respect cultural and religious values in palliative care [27].

Working collaboratively with religious figures (such as imams or priests) can help bridge gaps. For example, if an imam understands the medical perspective, he might help a family find religious justification for hospice or comfort care, rather than feeling it conflicts with faith.

Likewise, educating families that opting for palliative care is not equivalent to "giving up hope" but rather a shift in focus to quality of life can be framed in spiritually supportive terms (e.g., emphasizing compassion, dignity, and relief of suffering, which are values honored in most religions). The ultimate goal is to ensure that religious beliefs are acknowledged and supported by the medical team, so that patients and families feel their spiritual needs are met. When patients perceive that their healthcare providers respect their faith and will help incorporate it (for instance by facilitating prayer times, or allowing religious rituals in the hospital), trust and satisfaction improve. This can ease decision-making and reduce anxiety. Many Turkish patients derive strength from reciting prayers like the Quranic surahs or from having amulets and are relieved when these practices are accommodated during hospital stays.

Similarly, Western studies have shown that when spiritual support is provided by the medical system (not only by the patient's own community), patients experience better quality of life and are more likely to accept hospice services [30].

Thus, thoracic surgeons should be aware of their patients' beliefs and, where possible, engage chaplaincy services or the patient's own clergy, especially as disease advances.

The influence of social support and religious belief becomes perhaps most pronounced in the context of palliative care. Palliative care, by definition, addresses not just the physical symptoms of serious illness but also the psychosocial and spiritual needs of patients and their families [27].

Thoracic malignancies like lung cancer can often reach a stage where cure is not possible and the focus shifts to comfort and quality of life. At this juncture, the presence of a strong support system and the patient's spiritual framework can dramatically shape the experience. Patients with robust family support often can be cared for at home or in hospice, surrounded by loved ones, which many find more comforting than a hospital environment. Family members become the front-line providers of care in home hospice settings – managing medications, assisting with breathing exercises, providing nourishment, and simply being there to alleviate loneliness and fear. This caregiving can be demanding and emotionally draining. It is not uncommon for family caregivers of terminal thoracic patients to suffer from burnout, anxiety, or depression themselves. In a National Cancer Institute survey of cancer caregivers, 43% reported needing help to manage their emotional and physical stress, and 40% wanted more guidance with making end-of-life decisions for their loved one [31].

Caregivers are often juggling roles: trying to keep the patient comfortable, dealing with medical equipment or symptoms (like

home oxygen for lung disease), and grappling with anticipatory grief. Studies in various countries report high prevalence of caregiver burden – often nearly half of family caregivers of cancer patients experience significant burden or psychological morbidity [32] waocp.com. In Turkey, traditionally, the extended family would share caregiving duties, but with smaller families now, a tremendous load can fall on, say, one spouse or one adult child. If these individuals are not supported, they may become isolated or overwhelmed. A Turkish review on palliative practice pointed out the "isolation of family members who take part in the care process" and the "lack of support for them" as key challenges in the current system [27]. This underlines a critical point: caring for the caregivers is an essential part of caring for the patient. Palliative care teams, where available, often provide respite services, caregiver support groups, or at least training and education to family members on how to care for a bedridden patient, how to prevent pressure sores, how to give pain medication, etc. These interventions can ease caregiver burden and improve the patient's care. Moreover, a supported, educated caregiver is better equipped to manage symptoms at home, potentially reducing emergency hospital visits for issues that can be handled in the home setting with proper guidance.

For the patient in palliative care, social and spiritual support can greatly enhance quality of life even as physical health declines. Meaningful interactions with family and friends help alleviate the sense of abandonment that terminal patients sometimes feel. Regular communication and presence can reduce anxiety and depression in patients. Indeed, low social support has been linked not only to higher rates of depression in lung cancer patients, but also to worse survival among those who are depressed [14].

Depression itself is common in advanced lung disease (affecting an estimated 20–40% of lung cancer patients) and is exacerbated by feelings of isolation [33].

One study of Turkish lung cancer patients found a negative correlation between perceived social support and depression/hopelessness levels [34].

. Patients who felt well-supported by family were less prone to despair; however, it was noted that as illness became more prolonged and debilitating, even family support tended to wane or become strained.

This highlights the need for sustained community or professional support in long illness trajectories – families may need external help to continue providing care compassionately over time. Additionally, maintaining social connections provides patients with a continued sense of identity and normalcy. For example, being able to chat with a friend about everyday topics or having grandchildren visit can momentarily lift a patient out of the "sick role" and remind them of life beyond illness.

Religious and spiritual care is equally vital in palliative situations. As physical cures become unlikely, many patients turn inward to questions of meaning, legacy, and beliefs about death and afterlife. In Turkey, an overwhelmingly common belief among Muslim patients is the acceptance of illness as God's will and an emphasis on patience (sabr) during suffering. This can give patients a sense of peace, especially if they feel they have made spiritual preparations. Some derive comfort from reciting prayers (dua) or having the Quran read at the bedside. Others may wish to reconcile with God or seek forgiveness, which can involve visits from religious advisors or performing certain rituals. The healthcare team should facilitate these practices when possible. Small gestures – like arranging space for prayer, allowing modesty measures according to Islamic norms, or timing procedures around religious holidays – can significantly improve a patient's and family's comfort. In one Iranian study, many palliative cancer patients emphasized the need

for healthcare professionals to understand their spiritual needs and to show respect for their religious practices as part of quality care [35].

In Western settings too, patients who receive attention to spiritual needs (for instance, through chaplain visits or discussions about what matters most to them spiritually) report higher satisfaction with their care. They also may be more likely to choose hospice or less intensive care if they feel at peace spiritually. Conversely, if spiritual needs are neglected, patients can experience existential distress – a form of suffering characterized by hopelessness, fear of the unknown, or feeling a loss of the meaning of life. Palliative care philosophies argue that such existential distress should be addressed on par with physical pain. For thoracic surgeons, who may primarily see their role as managing the disease, it is important to appreciate these dimensions because they influence how patients perceive their journey. A patient who is spiritually at peace might approach a high-risk surgery with less fear of death, or might be more accepting of palliative care if surgery or chemotherapy can no longer help. On the other hand, a patient who is spiritually anguished may have more difficulty with any transition in goals of care.

Throughout the surgical journey, from diagnosis to either survivorship or palliation, an integrated approach that weaves together medical excellence with psychosocial support yields the best outcomes. The World Health Organization's definition of palliative care explicitly includes "the quality of life of patients and their families" and calls for relief of suffering through addressing physical, psychosocial, and spiritual problems [27].

While this definition is aimed at end-of-life care, its ethos applies broadly: treating a thoracic patient as a whole person in a social context, not just treating a tumor or a pair of lungs. Thoracic

surgeons, intensivists, oncologists, and palliative care specialists increasingly work in teams, recognizing that addressing issues like anxiety, social isolation, or cultural values is beyond the scope of surgery alone but crucial for overall outcomes. Empirical data support this approach. Early palliative care integration (which often involves intensive psychosocial support) in lung cancer has been shown to improve not only quality of life but even survival, as demonstrated in a landmark trial by Temel et al. and echoed by others [36].

That trial, though not specifically about social support, included attention to patients' social and emotional needs as part of palliative care and resulted in better mood and longer median survival for those receiving early palliative interventions.

From a global perspective, the interplay of social support and religion shows both universal themes and local variations. Universally, humans rely on their communities in times of illness – whether it's a spouse in New York driving a patient to chemotherapy, or a village in Anatolia coming together to prepare meals for a family with a sick elder. Universally, many facing mortality will ponder spiritual questions and reach for faith or philosophy to make sense of their experiences. What differs is how these supports are structured and valued in each healthcare system and culture. In Western countries, there might be formal support groups and professional counselors; in Turkey, one might see family taking greater charge and religious faith playing a more overt role in decision-making. Neither approach is inherently better – each has strengths and potential pitfalls. In Turkey, the strong family involvement can lead to excellent emotional support and hands-on care, but it can also result in families overruling a patient's autonomous wishes or keeping painful truths from them out of protective instinct. In more individualistic societies, patients might be well informed and autonomous but at risk of facing illness alone

if they lack family ties. This comparison underscores why healthcare providers should tailor their approach to the individual patient's context. A Turkish thoracic patient with dozens of concerned relatives and a devout outlook may need a different style of communication (perhaps involving family meetings and gentle navigation of religious expectations) compared to an American patient who lives alone and values independent decision-making.

Crucially, evidence-based medicine is increasingly affirming that attending to these psychosocial dimensions is not just "nice to have," but can alter hard outcomes. Early implementation of comprehensive supportive care has measurable benefits. For example, an interdisciplinary supportive care intervention for lung cancer patients after surgery (including social work, rehabilitation, and symptom management) led to clinically significant improvements in quality of life and distress levels at 12 months post-surgery [37].

In conclusion, thoracic surgeons and the teams they work with should recognize that every patient comes as part of a social unit and often with a set of beliefs that will accompany them through surgery and beyond. Just as meticulous surgical technique and evidence-based perioperative care protocols improve clinical outcomes, so does the "less visible" support surrounding the patient. Family involvement, if properly guided, can be harnessed to improve recovery, reduce complications, and provide comfort. Institutional and community supports extend the continuum of care beyond the hospital, preventing patients from falling through the cracks once they leave the operating theater. Peer support offers understanding and hope that enrich the patient's journey. And religious or spiritual belief, when respected and integrated, can be a wellspring of strength rather than a source of conflict. For thoracic surgery patients in particular – who may deal with cancers that have high morbidity or mortality – these psychosocial dimensions often distinguish a

patient's experience as either tolerable and meaning-filled or anguished and isolated. Whether in Turkey or elsewhere, the ultimate aim is to treat "the whole patient." This means surgeons should collaborate with psycho-oncology services, social workers, palliative care specialists, chaplains, and, importantly, the patient's family to craft a support plan alongside the surgical plan. By acknowledging and addressing social support mechanisms and religious beliefs, thoracic surgeons can greatly enhance patient outcomes and quality of life, from the first clinic visit through surgery, rehabilitation, and, when needed, the final stages of life.

Conclusion

The integration of palliative care within the field of thoracic surgery represents a paradigm shift towards a more humane, compassionate approach that addresses the full spectrum of patient needs. Palliative techniques in thoracic surgery, including symptom management and minimally invasive procedures, are crucial for enhancing patient comfort and quality of life. Furthermore, the roles of social support, family involvement, and religious beliefs are indispensable in providing a holistic care experience that respects patient values and cultural contexts.

Successful palliative care in thoracic surgery requires a multidisciplinary approach. Surgeons, nurses, pain specialists, social workers, and chaplains must work in unison to tailor care to the individual needs of each patient. Early integration of palliative care can significantly improve physical and emotional outcomes for patients, and proactive communication ensures that treatment aligns with patient and family expectations.

Ultimately, palliative care in thoracic surgery is not just about extending life but enhancing the quality of that life. As this field continues to evolve, it will require ongoing collaboration, research, and education to refine and optimize care strategies, ensuring that all

patients receive the compassion, respect, and dignity they deserve at the end of life.

References

1.Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. Eur J Heart Fail. 2020 Dec;22(12):2340-2346. doi: 10.1002/ejhf.1783. Epub 2020 Mar 16. PMID: 32176831.

2.Pinto S, Lopes S, de Sousa AB, Delalibera M, Gomes B. Patient and Family Preferences About Place of End-of-Life Care and Death: An Umbrella Review. J Pain Symptom Manage. 2024 May;67(5):e439-e452. doi: 10.1016/j.jpainsymman.2024.01.014. Epub 2024 Jan 17. PMID: 38237790.

3.Feliciano DR, Reis-Pina P. Enhancing End-of-Life Care With Home-Based Palliative Interventions: A Systematic Review. J Pain Symptom Manage. 2024 Nov;68(5):e356-e372. doi: 10.1016/j.jpainsymman.2024.07.005. Epub 2024 Aug 3. PMID: 39002710.

4.Collier A, Dadich A, Jeffs C, Noble A, Crawford GB. 'The palliative care ambulance': A qualitative study of patient and caregiver perspectives of an ambulance service. Palliat Med. 2023 Jun;37(6):875-883. doi: 10.1177/02692163231166760. Epub 2023 Apr 24. PMID: 37092529; PMCID: PMC10227093.

5.Samson P, Waters EA, Meyers B, Politi MC. Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer.

Ann Thorac Surg. 2016 Jun;101(6):2049-52. doi: 10.1016/j.athoracsur.2016.02.086. PMID: 27211932.

6.Ferrell BR, Twaddle ML, Melnick A, Meier DE. National Consensus Project Clinical Practice Guidelines for Quality Palliative Care Guidelines, 4th Edition. J Palliat Med. 2018 Dec;21(12):1684-1689. doi: 10.1089/jpm.2018.0431. Epub 2018 Sep 4. PMID: 30179523.

7.Davis MP, Bruera E, Morganstern D. Early integration of palliative and supportive care in the cancer continuum: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2013:144-50. doi: 10.14694/EdBook_AM.2013.33.144. PMID: 23714482.

8.Zhi WI, Smith TJ. Early integration of palliative care into oncology: evidence, challenges and barriers. Ann Palliat Med. 2015 Jul;4(3):122-31. doi: 10.3978/j.issn.2224-5820.2015.07.03. PMID: 26231808.

9.Foo CT, Pulimood T, Knolle M, Marciniak SJ, Herre J. Ambulatory Thoracoscopic Pleurodesis Combined With Indwelling Pleural Catheter in Malignant Pleural Effusion. Front Surg. 2021 Oct 25;8:738719. doi: 10.3389/fsurg.2021.738719. PMID: 34760917; PMCID: PMC8572984.

10.Shepherd RW, Radchenko C. Bronchoscopic ablation techniques in the management of lung cancer. Ann Transl Med. 2019 Aug;7(15):362. doi: 10.21037/atm.2019.04.47. PMID: 31516908; PMCID: PMC6712260.

11.Jayadevappa R, Chhatre S, Soukiasian HJ, Murgu S. Outcomes of patients with advanced non-small cell lung cancer and airway obstruction treated with photodynamic therapy and non-photodynamic therapy ablation modalities. J Thorac Dis. 2019 Oct;11(10):4389-4399. doi: 10.21037/jtd.2019.04.60. PMID: 31737325; PMCID: PMC6837945.

12.Mustola ST, Lempinen J, Saimanen E, Vilkko P. Efficacy of thoracic epidural analgesia with or without intercostal nerve cryoanalgesia for postthoracotomy pain. Ann Thorac Surg. 2011 Mar;91(3):869-73. doi: 10.1016/j.athoracsur.2010.11.014. PMID: 21353017.

13.Aung EY, Khan M, Williams N, Raja U, Hamady M. Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2022 Sep;45(9):1236-1254. doi: 10.1007/s00270-022-03178-z. Epub 2022 Jul 12. PMID: 35821122; PMCID: PMC9458578.

14.Hofman A, Zajdel N, Klekowski J, Chabowski M. Improving Social Support to Increase QoL in Lung Cancer Patients. Cancer Manag Res. 2021 Mar 11;13:2319-2327. doi: 10.2147/CMAR.S278087. PMID: 33732024; PMCID: PMC7959197.

15.Cardoso-Moreno MJ, Tomás-Aragones L. The influence of perceived family support on post surgery recovery. Psychol Health Med. 2017 Jan;22(1):121-128. doi:

10.1080/13548506.2016.1153680. Epub 2016 Feb 22. PMID: 26899740.

16.Mitchinson AR, Kim HM, Geisser M, Rosenberg JM, Hinshaw DB. Social connectedness and patient recovery after major operations. J Am Coll Surg. 2008 Feb;206(2):292-300. doi: 10.1016/j.jamcollsurg.2007.08.017. Epub 2007 Nov 12. PMID: 18222382.

17.Wang, Y-Y., *et al*. (2019) Effect of the Tailored, Family-Involved Hospital Elder Life Program on Postoperative Delirium and Function in Older Adults, A Randomized Clinical Trial. *JAMA Internal Medicine*. doi.org/10.1001/jamainternmed.2019.4446.

18.Muishout G, Topcu N, de la Croix A, Wiegers G, van Laarhoven HW. Turkish imams and their role in decision-making in palliative care: A Directed Content and Narrative analysis. Palliat Med. 2022 Jun;36(6):1006-1017. doi: 10.1177/02692163221095200. PMID: 35848214; PMCID: PMC9174576.

19.Cetin Z, Ozen B. Investigating spiritual care perceptions and religious coping methods among the relatives of terminally ill patients during the COVID-19 pandemic: the case of Turkey. BMC Palliat Care. 2024;23:131. doi: 10.1186/s12904-024-01463-x.

20.Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013 Nov 1;31(31):3869-3876. doi:

10.1200/JCO.2013.49.6489. PMID: 24062405; PMCID: PMC4878087.

21.Gu W, Xu YM, Zhong BL. Health-related quality of life in Chinese inpatients with lung cancer treated in large general hospitals: a cross-sectional study. BMJ Open. 2018 Apr 24;8(4):e019873. doi: 10.1136/bmjopen-2017-019873. PMID: 29691245; PMCID: PMC5922485.

22.Wang B, et al. Marital Status and Survival in Patients with Lung Cancer. J Thorac Oncol. 2018;13(10):S829.

23.Jatoi A, Novotny P, Cassivi S, Clark MM, Midthun D, Patten CA, et al. Does marital status impact survival and quality of life in patients with non-small cell lung cancer? Observations from the mayo clinic lung cancer cohort. Oncologist. 2007 Dec;12(12):1456-1463. doi: 10.1634/theoncologist.12-12-1456. PMID: 18165623.

24.Luszczynska A, Boehmer S, Knoll N, Schulz U, Schwarzer R. Emotional support for men and women with cancer: do patients receive what their partners provide? Int J Behav Med. 2007;14(3):156-163. doi: 10.1007/BF03000187. PMID: 17854287.

25.Ahmadi N, Mbuagbaw L, Finley C, Agzarian J, Hanna WC, Shargall Y. Impact of the integrated comprehensive care program post-thoracic surgery: A propensity score–matched study. J Thorac Cardiovasc Surg. 2021;162(1). doi: 10.1016/j.jtcvs.2020.05.095.

26.Asif M, Cadel L, Kuluski K, Everall AC, Guilcher SJT. Patient and caregiver experiences on care transitions for adults with a hip fracture: a scoping review. Disabil Rehabil. 2019;42(24):3549–3558. doi: 10.1080/09638288.2019.1595181.

27.Gurhan N. Palliative care: its importance and the practice in Turkey. Austin Palliat Care. 2016;1(1):1003.

28.John LD. Self-care strategies used by patients with lung cancer to promote quality of life. Oncol Nurs Forum. 2010 May;37(3):339-347. doi: 10.1188/10.ONF.339-347. PMID: 20439218.

29.Dogan N, Tan M. Quality of life and social support in patients with lung cancer. Int J Caring Sci. 2019;12(1):263.

30.Santos Carmo B, et al. Relationship Between Religion/Spirituality and the Aggressiveness of Cancer Care: A Scoping Review. J Pain Symptom Manage. 2023;65(5):e425-e437.

31.Litzelman K, Green PA, Yabroff KR. Cancer and quality of life in spousal dyads: spillover in couples with and without cancer-related health problems. Support Care Cancer. 2016 Feb;24(2):763-771. doi: 10.1007/s00520-015-2840-4. PMID: 26143040; PMCID: PMC4690790.

32.Karimi Moghaddam Z, Rostami M, Zeraatchi A, Mohammadi Bytamar J, Saed O, Zenozian S. Caregiving burden, depression, and anxiety among family caregivers of patients with

cancer: An investigation of patient and caregiver factors. Front Psychol. 2023 Mar 28;14:1059605. doi: 10.3389/fpsyg.2023.1059605.

33.Nipp RD, El-Jawahri A, Fishbein JN, Eusebio J, Stagl JM, Gallagher ER, et al. The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. Cancer. 2016 Jul 1;122(13):2110-2116. doi: 10.1002/cncr.30025. PMID: 27089045; PMCID: PMC5160928.

34.Şahin ZA, Tan M, Polat H. Hopelessness, depression and social support with end of life Turkish cancer patients. Asian Pac J Cancer Prev. 2013;14(5):2823-2828. PMID: 23803038.

35.Akcakaya A, Can G. The Role of Faith in Coping with Cancer among Palliative Care Patients in Turkey. In: Global Perspectives in Cancer Care: Religion, Spirituality, and Cultural Diversity in Health and Healing. Oxford: Oxford Academic; 2022. doi: 10.1093/med/9780197551349.003.0020. Accessed 26 Mar 2025.

36.Lee JL, Jeong Y. Quality of Life in Patients With Non-Small Cell Lung Cancer: Structural Equation Modeling. Cancer Nurs. 2019 Nov-Dec;42(6):475-483. doi: 10.1097/NCC.0000000000000645. PMID: 30204597.

37.Raz DJ, Sun V, Kim JY, Williams AC, Koczywas M, Cristea M, et al. Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical

Procedures. Ann Thorac Surg. 2016 Feb;101(2):495-502. doi: 10.1016/j.athoracsur.2015.07.031. PMID: 26443881; PMCID: PMC4718894.

.